MET and breast cancer: Meanwhile, we detected no significant pro‐apoptotic effect of the drug on both cell types, consistent to the report by Faggi L. et al.26 Moreover, our results supported advantage of combined MET + BC usage over BC alone for PRLoma treatment, considering cell proliferation, PRL secretion, and xenograft growth.